Cytokinetics (NASDAQ:CYTK) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Cytokinetics (NASDAQ:CYTK) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13, FiscalAI reports. The firm had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. During the same quarter in the prior year, the company earned ($1.12) EPS. The business’s revenue for the quarter was down 57.1% on a year-over-year basis.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO launch momentum exceeded expectations, with $25.3 million in Q2 net product revenue, 1,500 patients dispensed, more than 700 U.S. prescribers, and greater than 40% exit share of new-to-brand prescriptions. Medicare coverage reached nearly 90% parity, while commercial coverage exceeded 50%.
• Aficamten’s ACACIA-HCM Phase III trial met both primary endpoints in non-obstructive HCM, improving KCCQ scores and peak VO2 without new safety signals. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, potentially expanding MYQORZO to a substantially larger patient population.
• International expansion progressed with the German launch, U.K. marketing authorization and NICE reimbursement guidance, and reimbursement approval in the Netherlands. The company expects a U.K. launch later this year, followed by additional European launches through 2027.
• Cytokinetics ended Q2 with approximately $1.7 billion in cash and investments after raising $760 million, providing funding for commercialization and pipeline development. However, the net loss widened to $198.8 million, and full-year combined R&D and SG&A expense guidance was increased to $860 million–$890 million.
• The broader specialty-cardiology pipeline continued advancing, with COMET-HF enrolling more than one-third of patients, AMBER-HFpEF expected to complete its first cohort in the second half of 2026, and the adolescent cohort of CEDAR-HCM enrolling ahead of schedule.

Cytokinetics Price Performance

Shares of CYTK traded down $4.61 during midday trading on Friday, hitting $76.76. 3,604,418 shares of the company traded hands, compared to its average volume of 1,732,641. Cytokinetics has a one year low of $32.89 and a one year high of $88.31. The firm has a market cap of $9.55 billion, a P/E ratio of -10.63 and a beta of 0.38. The stock has a 50-day moving average of $78.91 and a 200-day moving average of $70.90.

Insider Activity at Cytokinetics

In related news, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $370,400.00. Following the sale, the director owned 15,784 shares of the company’s stock, valued at approximately $1,169,278.72. This represents a 24.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the completion of the sale, the executive vice president owned 58,555 shares in the company, valued at $4,337,754.40. This represents a 20.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 115,179 shares of company stock valued at $9,126,054. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Cytokinetics by 3.7% in the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after acquiring an additional 207,961 shares during the last quarter. Deep Track Capital LP lifted its stake in Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after purchasing an additional 650,000 shares during the last quarter. Vestal Point Capital LP lifted its stake in Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after purchasing an additional 384,469 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after buying an additional 1,435,422 shares in the last quarter. Finally, Northern Trust Corp grew its position in Cytokinetics by 2.0% during the third quarter. Northern Trust Corp now owns 1,406,832 shares of the biopharmaceutical company’s stock valued at $77,319,000 after acquiring an additional 27,641 shares during the last quarter.

Analyst Ratings Changes

Several research firms have commented on CYTK. Stifel Nicolaus increased their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada lowered their price objective on shares of Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a research report on Friday. Needham & Company LLC boosted their target price on shares of Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research note on Friday. Wells Fargo & Company boosted their target price on shares of Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $100.85.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.